• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受术前放疗/放化疗后达到完全病理缓解(pT0)的局部晚期或局部复发性直肠癌患者的临床结局。

Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer.

作者信息

Wiig Johan N, Larsen Stein G, Dueland Svein, Giercksky Karl-Erik

机构信息

Department of Surgical Oncology, The Norwegian Radium Hospital, Oslo, Norway.

出版信息

J Surg Oncol. 2005 Oct 1;92(1):70-5. doi: 10.1002/jso.20340.

DOI:10.1002/jso.20340
PMID:16180215
Abstract

BACKGROUND

The importance of pT0 stage after preoperative radiation/chemoradiation is unclear.

METHODS

Four hundred and nineteen patients had preoperative irradiation (46-50 Gy/2 Gy fractions) for primary locally advanced (PLA) or locally recurrent (LR) rectal cancer. 141 PLA and 65 LR cases with R0 resections/M0 stage are studied. Two of the pT0 PLA patients had also been given sensitizing chemotherapy and two pT0 in the LR group had received pelvic hyperthermia as well.

RESULTS

pT0 was achieved in 7% of 229 PLA and 8% of 190 LR patients. For the PLA group, actuarial 5-year survival of pT0 was 90% versus 53% for the pT > 0 group. The difference was statistically significant. At five years local recurrence was zero in pT0 patients versus 23% in pT > 0 (not significant). For the LR groups 5-year-survival was 62% for pT0 versus 45% for the other pT-stages, local recurrence was 17 and 35% respectively (not significant). The seemingly better results for pT0 cases of PLA cancers versus the LR ones did not reach statistical significance.

CONCLUSION

pT0 after preoperative irradiation is associated with improved survival for pT0 cases of PLA. Our studies on pT0 LR was suggestive of an improvement in this group as well.

摘要

背景

术前放疗/放化疗后pT0期的重要性尚不清楚。

方法

419例原发性局部进展期(PLA)或局部复发性(LR)直肠癌患者接受了术前照射(46 - 50 Gy,每次2 Gy)。对141例PLA和65例R0切除/M0期的LR病例进行了研究。2例pT0期PLA患者还接受了增敏化疗,LR组2例pT0期患者还接受了盆腔热疗。

结果

229例PLA患者中有7%达到pT0期,190例LR患者中有8%达到pT0期。对于PLA组,pT0期患者的5年精算生存率为90%,而pT>0组为53%。差异具有统计学意义。5年时,pT0期患者局部复发率为零,而pT>0组为23%(无统计学意义)。对于LR组,pT0期患者的5年生存率为62%,其他pT分期患者为45%,局部复发率分别为17%和35%(无统计学意义)。PLA癌pT0期病例与LR病例相比,看似更好的结果未达到统计学意义。

结论

术前放疗后pT0期与PLA的pT0期病例生存率提高相关。我们对pT0期LR的研究也提示该组患者生存率有所提高。

相似文献

1
Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer.接受术前放疗/放化疗后达到完全病理缓解(pT0)的局部晚期或局部复发性直肠癌患者的临床结局。
J Surg Oncol. 2005 Oct 1;92(1):70-5. doi: 10.1002/jso.20340.
2
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.术前超分割放化疗用于既往盆腔放疗后的局部复发性直肠癌患者:一项多中心II期研究。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18.
3
Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?最终TNM分期是否是局部晚期直肠癌术前放化疗后生存情况的预测指标?
Ann Surg Oncol. 2007 Oct;14(10):2766-72. doi: 10.1245/s10434-007-9471-z. Epub 2007 Jun 6.
4
Preoperative radiotherapy in rectal cancer: treatment results of three different dose regimens.直肠癌术前放疗:三种不同剂量方案的治疗结果
J BUON. 2006 Apr-Jun;11(2):161-6.
5
Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age.75岁以上局部晚期或复发性直肠癌患者的手术及术前放疗
Colorectal Dis. 2006 Mar;8(3):177-85. doi: 10.1111/j.1463-1318.2005.00877.x.
6
Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer.术前放疗用于晚期原发性和复发性直肠癌的全盆腔脏器切除术。
Eur J Surg. 2002;168(1):42-8. doi: 10.1080/110241502317307562.
7
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.接受术前放化疗、手术及术中放疗的T3-4期或N+期直肠癌患者无病生存的预后因素。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1122-8. doi: 10.1016/j.ijrobp.2005.09.020. Epub 2006 Jan 6.
8
[Preliminary results of preoperative radiotherapy schedule in the treatment of rectal tumors].[术前放疗方案治疗直肠肿瘤的初步结果]
Radiol Med. 1997 Dec;94(6):658-63.
9
Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer.局部晚期直肠癌术前放疗及手术后的预后因素
Eur J Surg Oncol. 2008 Apr;34(4):410-7. doi: 10.1016/j.ejso.2007.05.012. Epub 2007 Jul 5.
10
Short versus conventional preoperative radiotherapy of rectal cancer: indications.直肠癌术前短程放疗与传统放疗:适应证
J BUON. 2007 Apr-Jun;12(2):227-32.

引用本文的文献

1
Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas.局部晚期和复发性直肠腺癌术前放化疗联合区域热疗的II期研究长期结果
Cancers (Basel). 2022 Jan 29;14(3):705. doi: 10.3390/cancers14030705.
2
Surgical treatment of locally recurrent rectal cancer: a narrative review.局部复发性直肠癌的外科治疗:一篇叙述性综述
Ann Transl Med. 2021 Jun;9(12):1026. doi: 10.21037/atm-21-2298.
3
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.
卡培他滨联合贝伐珠单抗和外照射放疗作为可切除局部晚期直肠腺癌术前治疗的 II 期随机试验:长期结果。
BMC Cancer. 2020 Nov 27;20(1):1164. doi: 10.1186/s12885-020-07661-z.
4
ASO Author Reflections: Addition of Induction Chemotherapy Prior to Neoadjuvant Chemo(Re)Irradiation in Patients with Locally Recurrent Rectal Cancer to Improve Long-Term Outcomes.ASO作者反思:在局部复发性直肠癌患者新辅助化疗(再)放疗前增加诱导化疗以改善长期预后。
Ann Surg Oncol. 2020 Sep;27(9):3514-3515. doi: 10.1245/s10434-020-08446-1. Epub 2020 Apr 7.
5
Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer.局部复发性直肠癌采用诱导化疗和放化疗治疗后,应答者的结局得到改善。
Ann Surg Oncol. 2020 Sep;27(9):3503-3513. doi: 10.1245/s10434-020-08362-4. Epub 2020 Mar 19.
6
Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer.使用直肠癌术前放化疗的临床参数预测肿瘤反应。
World J Gastroenterol. 2011 Dec 28;17(48):5310-6. doi: 10.3748/wjg.v17.i48.5310.
7
A prospective analysis of patient outcome following treatment of T3 rectal cancer with neo-adjuvant chemoradiotherapy and transanal excision.前瞻性分析新辅助放化疗联合经肛门切除术治疗 T3 期直肠癌患者的治疗效果。
Int J Colorectal Dis. 2012 Jun;27(6):759-64. doi: 10.1007/s00384-011-1388-0. Epub 2011 Dec 17.
8
Pelvic exenteration for advanced and recurrent malignancy.盆腔廓清术治疗晚期和复发性恶性肿瘤。
World J Surg. 2010 Sep;34(9):2177-84. doi: 10.1007/s00268-010-0637-7.
9
Adjuvant therapy for rectal cancer.直肠癌的辅助治疗。
Clin Colon Rectal Surg. 2007 Aug;20(3):167-81. doi: 10.1055/s-2007-984861.
10
Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases.可切除肝转移患者肝外结直肠癌的检测与管理
J Gastrointest Surg. 2007 Jul;11(7):929-44. doi: 10.1007/s11605-006-0067-x.